Specialty pharmaceutical company Transdel Pharmaceuticals (OTC: TDLP) has announced that JH Direct, Transdel’s licensing partner for its anti-cellulite product, has completed initial testing for the product with favourable results, according to the company.
Cellulite is a condition where fat is trapped in the skin, causing it to have dimples. The condition is common among women, but less so with men, and commonly develops near the thighs and the abdomen areas.
The initial tests were carried out with 24 subjects and consisted of observing the before-and -after results of applying the product over a 16 week period.
JH Direct has also initiated plans for a final test to be conducted over the course of 12 weeks by a third-party skin research centre.
The test will be similar to the initial test, but will also obtain additional measurements. If the final test is successfully completed, JH Direct plans to bring the product to market during the fourth quarter of 2010 or in early 2011.
Under the terms of the licensing agreement, JH Direct will pay Transdel initial royalty advances and a continuing licensing royalty on the sales of the anti-cellulite product.
The product will be initially launched through a direct response television campaign created and managed by JH Direct, followed by an expansion into the retail and wholesale distribution channels.
Transdel develops non-invasive, topically delivered products. The company’s proprietary assets include its Transdel technology and its Ketotransdel product. Its drug delivery system helps deliver drugs through the skin, instead of relying on the metabolism of the liver. Ketotransdel uses the Transdel technology to deliver ketoprofen, an anti-inflammatory drug, through the skin directly into the underlying tissues.